696 related articles for article (PubMed ID: 18989686)
1. Daptomycin in bone and joint infections: a review of the literature.
Rice DA; Mendez-Vigo L
Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686
[TBL] [Abstract][Full Text] [Related]
2. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
Rouse MS; Piper KE; Jacobson M; Jacofsky DJ; Steckelberg JM; Patel R
J Antimicrob Chemother; 2006 Feb; 57(2):301-5. PubMed ID: 16361330
[TBL] [Abstract][Full Text] [Related]
4. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
5. [In vitro activity of daptomycin against VRE and MRSA strains].
Aktaş G; Derbentli S
Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
[TBL] [Abstract][Full Text] [Related]
6. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
Vikram HR; Havill NL; Koeth LM; Boyce JM
J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
8. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections.
Finney MS; Crank CW; Segreti J
Curr Med Res Opin; 2005 Dec; 21(12):1923-6. PubMed ID: 16368041
[TBL] [Abstract][Full Text] [Related]
9. Emerging issues in the diagnosis and management of infections caused by multi-drug-resistant, gram-positive cocci.
Napolitano LM
Surg Infect (Larchmt); 2005; 6 Suppl 2():S-5-22. PubMed ID: 23577494
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis.
Lefebvre M; Jacqueline C; Amador G; Le Mabecque V; Miegeville A; Potel G; Caillon J; Asseray N
Int J Antimicrob Agents; 2010 Dec; 36(6):542-4. PubMed ID: 20851576
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria.
Rybak MJ
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721
[TBL] [Abstract][Full Text] [Related]
12. [Daptomycin therapy in patients with bacteremia].
Llinares P; Iribarren JA
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():17-25. PubMed ID: 22541971
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
Kanafani ZA; Corey GR
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
[TBL] [Abstract][Full Text] [Related]
14. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Carpenter CF; Chambers HF
Clin Infect Dis; 2004 Apr; 38(7):994-1000. PubMed ID: 15034832
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin: a new drug class for the treatment of Gram-positive infections.
Alder JD
Drugs Today (Barc); 2005 Feb; 41(2):81-90. PubMed ID: 15821781
[TBL] [Abstract][Full Text] [Related]
16. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL.
McDaneld PM; Spooner LM; Mohr JF; Belliveau PP
Ann Pharmacother; 2013 Dec; 47(12):1654-65. PubMed ID: 24259618
[TBL] [Abstract][Full Text] [Related]
17. Daptomycin, a lipopeptide antibiotic in clinical practice.
Weis F; Beiras-Fernandez A; Schelling G
Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin to bone and joint infections and prosthesis joint infections: a systematic review.
Telles JP; Cieslinski J; Tuon FF
Braz J Infect Dis; 2019; 23(3):191-196. PubMed ID: 31207214
[TBL] [Abstract][Full Text] [Related]
19. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature.
van Hal SJ; Paterson DL; Gosbell IB
Eur J Clin Microbiol Infect Dis; 2011 May; 30(5):603-10. PubMed ID: 21191627
[TBL] [Abstract][Full Text] [Related]
20. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
Steenbergen JN; Alder J; Thorne GM; Tally FP
J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
